Reverted Compound definition

Reverted Compound means, with respect to a Reverted Licensed Product, any Licensed Compound included in such Reverted Licensed Product.
Sample 1Sample 2Sample 3
Reverted Compound means a former Related Compound that Roivant has lost all rights to under this Agreement pursuant to Section 3.4 or a Compound for which Roivant has terminated its rights pursuant to Section 12.3.
Sample 1Sample 2
Reverted Compound means: (a) any Licensed Compound that has [*] prior to the effective date of termination of this Agreement; and (b) any Licensed Compound that: (i) has [*] prior to the effective date of termination of this Agreement; and (ii) are [*].
Sample 1

Examples of Reverted Compound in a sentence

  • For clarity, the licenses granted in Section 11.5 by BMS to Exelixis do not give Exelixis any right or license (a) to incorporate into any Product (e.g., as a combination product) any compound that is Controlled by Exelixis and that is not a Reverted Compound or (b) to perform any research that is directed to identifying, characterizing, developing or otherwise pursuing any small molecule compound that is not a Reverted Compound.

  • Agios and, subject to Sections 15.4(b) and 15.4(c), its Affiliates shall not, and shall not grant any Third Party the right to, Develop, Manufacture and/or Commercialize any Licensed Compound, Licensed Product, Celgene Reverted Compound or Celgene Reverted Product for any purpose, other than in connection with a Licensed Program or Celgene Reverted Program pursuant to the Collaboration under this Agreement.

  • Notwithstanding the foregoing, to the extent any such expenses relate to Patent Applications solely claiming Reverted Compounds, Curis Option Compounds or the manufacture or use thereof, Wyeth shall [**] reimburse Curis for any [**] Reverted Compound or a Curis Option Compound [**] with respect to such Reverted Compound or Curis Option Compound.

  • Additionally, all TRI reporters with foreign parent companies may be required to submit additional information (indicate the foreign parent company name or not applicable), depending on the regulatory option considered.

  • Such license grant is to Roche Know-How, Roche Patent Rights and Roche’s interest in the Joint Know-How and Joint Patent Rights Controlled by Roche as of the date such Licensed Compound, Product or Passed Compound becomes a Reverted Compound (and not to Roche Know-How, Roche Patent Rights and Roche’s interest in the Joint Know-How and Joint Patent Rights which Roche may acquire Control of after such date).

  • No settlement of any such action or defense which restricts the scope or affects the enforceability of a Reverted Compound Patent may be entered into by BMS without the prior consent of Exelixis (such consent to not be unreasonably withheld, delayed or conditioned).

  • In the event that management or in-house counsel for either Party becomes aware of a suspected infringement of a Patent that claims a Joint Invention but is not a Joint Product Patent or a Reverted Compound Patent (for purposes of this Section 8.4(c) only, an “Other Joint Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties shall confer.

  • With respect to any Reverted Compound, PTI will be free to (A) make public disclosures as it deems appropriate with respect to such Reverted Compound and (B) publish or have published information about clinical studies related to any such Reverted Compound or Reverted Product, including the results of such clinical study.

  • In the event that management or in-house counsel for either Party becomes aware of a suspected infringement of a Patent claiming a Joint Invention that pertains to the composition of matter, manufacture or use of a Reverted Compound and which is exclusively licensed to Exelixis under Section 10.4 (for purposes of this Section 8.4(c) only, a “Reverted Compound Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties shall confer.

  • Notwithstanding any exclusive license granted to PTI, Astellas will retain the right to use Collaboration Technology that Covers a Discontinued Compound, Reverted Compound or Reverted Product for its internal research purposes.


More Definitions of Reverted Compound

Reverted Compound means (i) a former [***] that has been [***] with another [***] pursuant to Section [***] or is [***] from [***] under Section [***]; provided that such [***] shall not be deemed a Reverted Compound [***] of the [***]; or (ii) any [***] for which [***] under Section [***](d) or Section [***](c) or for which the [***] has been terminated under Section [***].
Sample 1
Reverted Compound means: (a) any Licensed Compound that has [*] prior to the effective date of termination of this Agreement; and (b) any Licensed Compound that: (i) has [*] prior to the effective date of termination of this Agreement; and (ii) are [*]. 9 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Reverted Compound means an Adnectin, a Licensed Compound or a Licensed Product with respect to which BMS has granted a license to ATI pursuant to Section 17.5.
Sample 1
Reverted Compound means a Compound that reverts to Curis in accordance with Section 3.10.3 hereof.
Sample 1
Reverted Compound means any Active Compound that is (a) a Development Compound or Back-Up Compound at the time this Agreement is terminated (in its entirety or with respect to such Active Compound or its Project or any particular country in the Territory) for any reason other than by Astellas pursuant to Section 12.2(c) (Termination for Cause), or (b) a Claimed Compound at the time all Development or Commercialization with respect to the relevant Development Compound or Back-up Compound claimed in the patent Covering such Claimed Compound is terminated by Astellas pursuant to Section 2.3(h) (Claimed Compounds).
Sample 1

Related to Reverted Compound

  • Licensed Compound means [***].

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Exempt compound means the same as defined in Rule 2.

  • Compounds means any or all of the following chemicals, as the context requires:

  • Biosimilar Product means, with respect to a Licensed Product and on a country-by-country basis, a product that [***].

  • GSK has the meaning set forth in the preamble.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Licensed Product means a product or part of a product in the Licensed Field of Use: (A) the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or (B) which is made with, uses or incorporates any Technology.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Therapeutic Product means a health product categorised as a therapeutic product in the First Schedule to the Act;

  • Covered Product The consumer product that You purchased concurrently with and is covered by this Agreement.

  • Joint Patent Rights means Patent Rights that contain one or more claims that cover Joint Technology.

  • Patent Right means: (a) an issued or granted patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination, extension or restoration by existing or future extension or restoration mechanisms (including, without limitation, supplementary protection certificates or the equivalent thereof), or renewal thereof; (b) a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.

  • Product Technology means the Product Know-How and Product Patents.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Program Patent Rights means any Patent Rights that contain one or more claims that cover Program Inventions.